Literature DB >> 16326753

Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

Roy S Herbst1, Dean F Bajorin, Harry Bleiberg, Diane Blum, Desirée Hao, Bruce E Johnson, Robert F Ozols, George D Demetri, Patricia A Ganz, Mark G Kris, Bernard Levin, Maurie Markman, Derek Raghavan, Gregory H Reaman, Raymond Sawaya, Lynn M Schuchter, John W Sweetenham, Linda T Vahdat, Everett E Vokes, Rodger J Winn, Robert J Mayer.   

Abstract

This year, for the first time, the American Society of Clinical Oncology (ASCO) is publishing Clinical Cancer Advances 2005: Major Research Advances in Cancer Treatment, Prevention, and Screening, an annual review of the most significant clinical research presented or published over the past year across all cancer types. ASCO embarked on this project to provide the public, patients, policymakers, and physicians with an accessible summary of the year's most important research advances. While not intended to serve as a comprehensive review, this report provides a year-end snapshot of research that will have the greatest impact on patient care. As you will read, there is much good news from the front lines of cancer research. These pages report on new chemotherapy regimens that sharply reduce the risk of recurrence for very common cancers; the "coming of age" of targeted cancer therapies; promising studies of drugs to prevent cancer; and improvements in quality of life for people living with the disease, among many other advances. Survival rates for cancer are on the rise, increasing from 50% to 64% over the last 30 years. Cancer still exacts an enormous toll, however. Nearly 1.4 million Americans will be diagnosed this year, and some 570,000 will die of the disease. Clearly, more research is needed to find effective therapies for the most stubborn cancer types and stages. We need to know more about the long-term effects of newer, more targeted cancer therapies, some of which need to be taken over long periods of time. And we need to devote far greater attention to tracking and improving the care of the nearly 10 million cancer survivors in the United States today. Despite these and other challenges, the message of this report is one of hope. Through the dedicated, persistent pursuit of clinical research and participation in clinical trials by people with cancer, we steadily uncover new and better ways of treating, diagnosing, and preventing a disease that touches the lives of so many. I want to thank the Editorial Board members, the Specialty Editors, and the ASCO Cancer Communications Committee for their dedicated work to develop this report, and I hope you find it useful.

Entities:  

Mesh:

Year:  2005        PMID: 16326753     DOI: 10.1200/JCO.2005.04.8678

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  29 in total

1.  Evaluation of lung MDCT nodule annotation across radiologists and methods.

Authors:  Charles R Meyer; Timothy D Johnson; Geoffrey McLennan; Denise R Aberle; Ella A Kazerooni; Heber Macmahon; Brian F Mullan; David F Yankelevitz; Edwin J R van Beek; Samuel G Armato; Michael F McNitt-Gray; Anthony P Reeves; David Gur; Claudia I Henschke; Eric A Hoffman; Peyton H Bland; Gary Laderach; Richie Pais; David Qing; Chris Piker; Junfeng Guo; Adam Starkey; Daniel Max; Barbara Y Croft; Laurence P Clarke
Journal:  Acad Radiol       Date:  2006-10       Impact factor: 3.173

2.  Development of clinical trials in a cooperative group setting: the eastern cooperative oncology group.

Authors:  David M Dilts; Alan Sandler; Steven Cheng; Joshua Crites; Lori Ferranti; Amy Wu; Robert Gray; Jean MacDonald; Donna Marinucci; Robert Comis
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

3.  The growing pains of cancer survivors: a call for a paradigm of interdisciplinary care.

Authors:  M Chasen; A Kennedy
Journal:  Curr Oncol       Date:  2013-04       Impact factor: 3.677

4.  WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis.

Authors:  Sireesha V Garimella; Andrea Rocca; Stanley Lipkowitz
Journal:  Mol Cancer Res       Date:  2011-11-23       Impact factor: 5.852

5.  Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010.

Authors:  Chenjie Zeng; Wanqing Wen; Alicia K Morgans; William Pao; Xiao-Ou Shu; Wei Zheng
Journal:  JAMA Oncol       Date:  2015-04       Impact factor: 31.777

6.  Major Advances in the Treatment of Cancer: What does a Non-Oncologist need to know?

Authors:  Ikram A Burney; Mansour S Al-Moundhri
Journal:  Sultan Qaboos Univ Med J       Date:  2008-07

7.  Follow-up care for cancer survivors: the views of clinicians.

Authors:  D M Greenfield; K Absolom; C Eiser; S J Walters; G Michel; B W Hancock; J A Snowden; R E Coleman
Journal:  Br J Cancer       Date:  2009-07-28       Impact factor: 7.640

8.  Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM).

Authors:  R Colomer; E Alba; A González-Martin; L Paz-Ares; M Martín; A Llombart; Á Rodríguez Lescure; J Salvador; J Albanell; D Isla; M Lomas; C A Rodríguez; J M Trigo; J R Germà; J Bellmunt; J Tabernero; R Rosell; E Aranda; R Cubedo; J Baselga
Journal:  Ann Oncol       Date:  2010-02       Impact factor: 32.976

9.  Semi-automated volumetric analysis of lymph node metastases in patients with malignant melanoma stage III/IV--a feasibility study.

Authors:  M Fabel; H von Tengg-Kobligk; F L Giesel; L Bornemann; V Dicken; A Kopp-Schneider; C Moser; S Delorme; H-U Kauczor
Journal:  Eur Radiol       Date:  2008-02-15       Impact factor: 5.315

10.  Utilization of genomic signatures to identify phenotype-specific drugs.

Authors:  Seiichi Mori; Jeffrey T Chang; Eran R Andrechek; Anil Potti; Joseph R Nevins
Journal:  PLoS One       Date:  2009-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.